Redox homeostasis and cellular antioxidant systems: Crucial players in cancer growth and therapy

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Marengo, Barbara ^a   Nitti, Mariapaola ^a   Furfaro, Anna Lisa ^b   Colla, Renata ^a   Ciucis, Chiara De ^a   Marinari, Umberto Maria ^a   Pronzato, Maria Adelaide ^a   Traverso, Nicola ^a   Domenicotti, Cinzia ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANTS; CELLS; CHEMOTHERAPY; CYTOLOGY; DISEASES; OXYGEN; PHYSIOLOGY; SIGNALING;

ANTIOXIDANT ENZYME; ANTIOXIDANT SYSTEMS; CELLULAR PHYSIOLOGY; PHYSIOLOGICAL CONDITION; REACTIVE OXYGEN SPECIES; SIGNALING PATHWAYS; SUPEROXIDE DISMUTASES; TUMOR PROGRESSIONS;

CELL SIGNALING;

ANTINEOPLASTIC AGENT; ANTIOXIDANT; APOPTOSIS SIGNAL REGULATING KINASE 1; ARSENIC TRIOXIDE; ATM PROTEIN; BILIRUBIN; BORTEZOMIB; CATALASE; DISULFIRAM; EZATIOSTAT; FERRITIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HYPOXIA INDUCIBLE FACTOR 1; IMEXON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEVO BUTHIONINE S,R SULFOXIMINE; MENADIONE; NOV 002; PEROXIREDOXIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; THIOREDOXIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2; UBIQUINONE; UNCLASSIFIED DRUG;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CELL DAMAGE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; HOMEOSTASIS; HUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; REVIEW; SCAVENGING SYSTEM; TUMOR GROWTH; ANIMAL; CLINICAL TRIAL (TOPIC); METABOLISM; NEOPLASMS; OXIDATION REDUCTION REACTION; PATHOLOGY;

ANIMALS; ANTIOXIDANTS; CARCINOGENESIS; CLINICAL TRIALS AS TOPIC; HOMEOSTASIS; HUMANS; NEOPLASMS; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES;

EID: 84978646245     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/6235641     Document Type: Review

References (233)

1. H. Wiseman and B. Halliwell, "Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer, " Biochemical Journal, vol. 313, no. 1, pp. 17-29, 1996.
2. T. Finkel, "Signal transduction by mitochondrial oxidants, " The Journal of Biological Chemistry, vol. 287, no. 7, pp. 4434-4440, 2012.
3. Y. M. W. Janssen-Heininger, B. T. Mossman, N. H. Heintz, et al., "Redox-based regulation of signal transduction: principles, pitfalls, and promises, " Free Radical Biology and Medicine, vol. 45, no. 1, pp. 1-17, 2008.
4. H. J. Forman, M. Torres, and J. Fukuto, "Redox signaling, " Molecular and Cellular Biochemistry, vol. 234-235, pp. 49-62, 2002.
5. L.-Z. Liu, X.-W. Hu, C. Xia, et al., "Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1β expression through activation of AKT and P70S6K1 in human ovarian cancer cells, " Free Radical Biology and Medicine, vol. 41, no. 10, pp. 1521-1533, 2006.
6. S. Zhou, S. Kachhap, W. Sun, et al., "Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 18, pp. 7540-7545, 2007.
7. M. Benhar, D. Engelberg, and A. Levitzki, "ROS, stressactivated kinases and stress signaling in cancer, " EMBO Reports, vol. 3, no. 5, pp. 420-425, 2002.
8. C. Pantano, N. L. Reynaert, A. van der Vliet, and Y. M. W. Janssen-Heininger, "Redox-sensitive kinases of the nuclear factor-κB signaling pathway, " Antioxidants and Redox Signaling, vol. 8, no. 9-10, pp. 1791-1806, 2006.
9. E. B. Rankin and A. J. Giaccia, "The role of hypoxia-inducible factors in tumorigenesis, " Cell Death and Differentiation, vol. 15, no. 4, pp. 678-685, 2008.
10. J. M. McCord and I. Fridovich, "Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein), " Journal of Biological Chemistry, vol. 244, no. 22, pp. 6049-6055, 1969.
11. Y. Li, T.-T. Huang, E. J. Carlson, et al., "Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase, " Nature Genetics, vol. 11, no. 4, pp. 376-381, 1995.
12. C. G. Pham, C. Bubici, F. Zazzeroni, et al., "Ferritin heavy chain upregulation by NF-κB inhibits TNFα-induced apoptosis by suppressing reactive oxygen species, " Cell, vol. 119, no. 4, pp. 529-542, 2004.
13. D. Kang, K.-M. Lee, K. P. Sue, et al., "Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study, " Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 8, pp. 1581-1586, 2007.
14. G. Liu, W. Zhou, L. I. Wang, et al., "MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinoma, " Cancer Letters, vol. 214, no. 1, pp. 69-79, 2004.
15. S. H. Olson, M. D. A. Carlson, H. Ostrer, et al., "Genetic variants in SOD2, MPO, andNQO1, and risk of ovarian cancer, " Gynecologic Oncology, vol. 93, no. 3, pp. 615-620, 2004.
16. S. S. Wang, S. Davis, J. R. Cerhan, et al., "Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma, " Carcinogenesis, vol. 27, no. 9, pp. 1828-1834, 2006.
17. G. Ray, S. Batra, N. K. Shukla, et al., "Lipid peroxidation, free radical production and antioxidant status in breast cancer, " Breast Cancer Research and Treatment, vol. 59, no. 2, pp. 163-170, 2000.
18. F. Tas, H. Hansel, A. Belce, et al., "Oxidative stress in breast cancer, " Medical Oncology, vol. 22, no. 1, pp. 11-15, 2005.
19. J. Yang, E. W. N. Lam, H. M. Hammad, T. D. Oberley, and L. W. Oberley, "Antioxidant enzyme levels in oral squamous cell carcinoma and normal human oral epithelium, " Journal of Oral Pathology and Medicine, vol. 31, no. 2, pp. 71-77, 2002.
20. J. J. Cullen, F. A. Mitros, and L. W. Oberley, "Expression of antioxidant enzymes in diseases of the human pancreas: another link between chronic pancreatitis and pancreatic cancer, " Pancreas, vol. 26, no. 1, pp. 23-27, 2003.
21. R. Kumaraguruparan, J. Kabalimoorthy, and S. Nagini, "Correlation of tissue lipid peroxidation and antioxidants with clinical stage and menopausal status in patients with adenocarcinoma of the breast, " Clinical Biochemistry, vol. 38, no. 2, pp. 154-158, 2005.
22. I. Beno, M. Staruchova, K. Vokovova, and M. Batovsky, "Increased antioxidant enzyme activities in the colorectal adenoma and carcinoma, " Neoplasma, vol. 42, no. 5, pp. 265-269, 1995.
23. K. Kahlos, S. Anttila, T. Asikainenet al., "Manganese superoxide dismutase in healthy human pleuralmesotheliumand inmalignant pleural mesothelioma, " American Journal of Respiratory Cell and Molecular Biology, vol. 18, no. 4, pp. 570-580, 1998.
24. A. Perkins, K. J. Nelson, D. Parsonage, L. B. Poole, and P. A. Karplus, "Peroxiredoxins: guardians against oxidative stress and modulators of peroxide signaling, " Trends in Biochemical Sciences, vol. 40, no. 8, pp. 435-445, 2015.
25. M. H. Park, M. Jo, Y. R. Kim, et al., "Roles of peroxiredoxins in cancer, neurodegenerative diseases and inflammatory diseases, " Pharmacology &Therapeutics, vol. 163, pp. 1-23, 2016.
26. R. A. Egler, E. Fernandes, K. Rothermund, et al., "Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1, " Oncogene, vol. 24, no. 54, pp. 8038-8050, 2005.
27. J. Cao, J. Schulte, A. Knight, et al., "Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity, " The EMBO Journal, vol. 28, no. 10, pp. 1505-1517, 2009.
28. V. L. Kinnula, S. Lehtonen, R. Sormunen, et al., "Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma, " Journal of Pathology, vol. 196, no. 3, pp. 316323, 2002.
29. S. T. Lehtonen, A.-M. Svensk, Y. Soini, et al., "Peroxiredoxins, a novel protein family in lung cancer, " International Journal of Cancer, vol. 111, no. 4, pp. 514-521, 2004.
30. T. Yanagawa, S. Iwasa, T. Ishii, et al., "Peroxiredoxin I expression in oral cancer: a potential new tumor marker, " Cancer Letters, vol. 156, no. 1, pp. 27-35, 2000.
31. J. Shen, M. D. Person, J. Zhu, J. L. Abbruzzese, and D. Li, "Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry, " Cancer Research, vol. 64, no. 24, pp. 9018-9026, 2004.
32. W. Lu, Z. Fu, H. Wang, J. Feng, J. Wei, and J. Guo, "Peroxiredoxin is upregulated in colorectal cancer and contributes to colorectal cancer cells survival by protecting cells from oxidative stress, "Molecular and Cellular Biochemistry, vol. 387, no. 1-2, pp. 261-270, 2014.
33. M. Shiota, A. Yokomizo, E. Kashiwagi, et al., "Peroxiredoxin in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells, " Free Radical Biology and Medicine, vol. 51, no. 1, pp. 78-87, 2011.
34. Y.-G. Wang, L. Li, C.-H. Liu, S. Hong, and M.-J. Zhang, "Peroxiredoxin 3 is resistant to oxidation-induced apoptosis of Hep-3b cells, " Clinical and Translational Oncology, vol. 16, no. 6, pp. 561-566, 2014.
35. H. C. Whitaker, D. Patel, W. J. Howat, et al., "Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells fromoxidative stress, " British Journal of Cancer, vol. 109, no. 4, pp. 983-993, 2013.
36. Q. Wei, H. Jiang, Z. Xiao, et al., "Sulfiredoxin-Peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 17, pp. 7004-7009, 2011.
37. T. H. Kim, J. Song, S. R. Alcantara Llaguno, et al., "Suppression of peroxiredoxin 4 in glioblastoma cells increases apoptosis and reduces tumor growth, " PLoS ONE, vol. 7, no. 8, Article ID e42818, 2012.
38. A. Elamin, H. Zhu, A. M. Hassan, et al., "Peroxiredoxin V: a candidate breast tumor marker of population specificity, " Molecular and Clinical Oncology, vol. 1, no. 3, pp. 541-549, 2013.
39. H.-M. Yun, K.-R. Park, M. H. Park, et al., "PRDX6 promotes tumor development via the JAK2/STAT3 pathway in a urethaneinduced lung tumor model, " Free Radical Biology andMedicine, vol. 80, pp. 136-144, 2015.
40. T. Tanaka, F. Hosoi, Y. Yamaguchi-Iwai, et al., "Thioredoxin (TRX-2) is an essential gene regulating mitochondriadependent apoptosis, " The EMBO Journal, vol. 21, no. 7, pp. 1695-1703, 2002.
41. N. Turunen, P. Karihtala, A. Mantyniemi, et al., "Thioredoxin is associated with proliferation, p53 expression and negative estrogen and progesterone receptor status in breast carcinoma, " Acta Pathologica, Microbiologica et Immunologica Scandinavica, vol. 112, no. 2, pp. 123-132, 2004.
42. S. Fujii, Y. Nanbu, H. Nonogaki, et al., "Coexpression of adult Tcell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium, " Cancer, vol. 68, no. 7, pp. 1583-1591, 1991.
43. H. Nakamura, H. Masutani, Y. Tagaya, et al., "Expression and growth-promoting effect of adult T-cell leukemia-derived factor: a human thioredoxin homologue in hepatocellular carcinoma, " Cancer, vol. 69, no. 8, pp. 2091-2097, 1992.
44. Y. Soini, K. Kahlos, U. Napankangas, et al., "Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma, " Clinical Cancer Research, vol. 7, no. 6, pp. 1750-1757, 2001.
45. D. T. Lincoln, E. M. Ali Emadi, K. F. Tonissen, and F. M. Clarke, "The thioredoxin-thioredoxin reductase system: overexpression in human cancer, " Anticancer Research, vol. 23, no. 3B, pp. 2425-2433, 2003.
46. H. Sies, "Glutathione and its role in cellular functions, " Free Radical Biology andMedicine, vol. 27, no. 9-10, pp. 916-921, 1999.
47. O. W. Griffith, "Biologic and pharmacologic regulation of mammalian glutathione synthesis, " Free Radical Biology and Medicine, vol. 27, no. 9-10, pp. 922-935, 1999.
48. N. Traverso, R. Ricciarelli, M. Nitti, et al., "Role of glutathione in cancer progression and chemoresistance, " OxidativeMedicine and Cellular Longevity, vol. 2013, Article ID 972913, 10 pages, 2013.
49. I. S. Harris, A. E. Treloar, S. Inoue, et al., "Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression, " Cancer Cell, vol. 27, no. 2, pp. 211-222, 2015.
50. G. Ravn-Haren, A. Olsen, A. Tjonneland, et al., "Associations between GPX1 Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and breast cancer risk in a prospective cohort study, " Carcinogenesis, vol. 27, no. 4, pp. 820-825, 2006.
51. Z. Arsova-Sarafinovska, N. Matevska, A. Eken, et al., "Glutathione peroxidase 1 (GPX1) genetic polymorphism, erythrocyte GPX activity, and prostate cancer risk, " International Urology and Nephrology, vol. 41, no. 1, pp. 63-70, 2009.
52. O. Raaschou-Nielsen, M. Sorensen, R. D. Hansen, et al., "GPX1 Pro198Leu polymorphism, interactions with smoking and alcohol consumption, and risk for lung cancer, " Cancer Letters, vol. 247, no. 2, pp. 293-300, 2007.
53. Y. Ichimura, T. Habuchi, N. Tsuchiya, et al., "Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon variant, " The Journal of Urology, vol. 172, no. 2, pp. 728-732, 2004.
54. M. D. Maines, "Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications, " FASEB Journal, vol. 2, no. 10, pp. 2557-2568, 1988.
55. S. M. Keyse and R. M. Tyrrell, "Heme oxygenase is themajor 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodiumarsenite, " Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 1, pp. 99-103, 1989.
56. S. W. Ryter and A. M. K. Choi, "Heme oxygenase-1: redox regulation of a stress protein in lung and cell culture models, " Antioxidants and Redox Signaling, vol. 7, no. 1-2, pp. 80-91, 2005.
57. A. Prawan, J. K. Kundu, and Y.-J. Surh, "Molecular basis of heme oxygenase-1 induction: implications for chemoprevention and chemoprotection, " Antioxidants and Redox Signaling, vol. 7, no. 11-12, pp. 1688-1703, 2005.
58. A. L. Furfaro, N. Traverso, C. Domenicotti, et al., "TheNrf2/HO axis in cancer cell growth and chemoresistance, " Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 1958174 pages, 2016.
59. A. Jozkowicz, H. Was, and J. Dulak, "Heme oxygenase-1 in tumors: is it a false friend?" Antioxidants and Redox Signaling, vol. 9, no. 12, pp. 2099-2117, 2007.
60. H. Was, T. Cichon, R. Smolarczyk, et al., "Overexpression of heme oxygenase-1 inmurinemelanoma: increased proliferation and viability of tumor cells, decreased survival of mice, " American Journal of Pathology, vol. 169, no. 6, pp. 2181-2198, 2006.
61. J.-R. Tsai, H.-M. Wang, P.-L. Liu, et al., "High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients, " Cellular Oncology, vol. 35, no. 6, pp. 461-471, 2012.
62. M. Hill, V. Pereira, C. Chauveau, et al., "Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2, 3-dioxygenase, " The FASEB Journal, vol. 19, no. 14, pp. 1957-1968, 2005.
63. C.-Y. Chao, C.-K. Lii, Y.-T. Hsu, et al., "Induction of heme oxygenase-1 and inhibition of TPA-induced matrix metalloproteinase-9 expression by andrographolide in MCF-7 human breast cancer cells, " Carcinogenesis, vol. 34, no. 8, pp. 1843-1851, 2013.
64. B. Wegiel, Z. Nemeth, M. Correa-Costa, A. C. Bulmer, and L. E. Otterbein, "Heme oxygenase-1: a metabolic nike, " Antioxidants and Redox Signaling, vol. 20, no. 11, pp. 1709-1722, 2014.
65. D. Tibullo, I. Barbagallo, C. Giallongo, et al., "Heme oxygenase nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells, " Oncotarget, vol. 7, no. 20, pp. 28868-28880, 2016.
66. D. Tibullo, I. Barbagallo, C. Giallongo, et al., "Nuclear translocation of Heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells, " Current Pharmaceutical Design, vol. 19, no. 15, pp. 2765-2770, 2013.
67. O. W. Griffith, "Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis, " Journal of Biological Chemistry, vol. 257, no. 22, pp. 13704-13712, 1982.
68. G. T. Wondrak, "Redox-directed cancer therapeutics:molecular mechanisms and opportunities, " Antioxidants and Redox Signaling, vol. 11, no. 12, pp. 3013-3069, 2009.
69. B. Marengo, C. De Ciucis, D. Verzola, et al., "Mechanisms of BSO (L-buthionine-S, R-sulfoximine)-induced cytotoxic effects in neuroblastoma, " Free Radical Biology and Medicine, vol. 44, no. 3, pp. 474-482, 2008.
70. B. Marengo, E. Balbis, S. Patriarca, et al., "GSH loss per se does not affect neuroblastoma survival and is not genotoxic, " International Journal ofOncology, vol. 32, no. 1, pp. 121-127, 2008.
71. B. Marengo, L. Raffaghello, V. Pistoia, et al., "Reactive oxygen species: biological stimuli of neuroblastoma cell response, " Cancer Letters, vol. 228, no. 1-2, pp. 111-116, 2005.
72. C. Domenicotti, B. Marengo, M. Nitti, et al., "A novel role of protein kinase C-δ in cell signaling triggered by glutathione depletion, " Biochemical Pharmacology, vol. 66, no. 8, pp. 1521-1526, 2003.
73. P. J. O'Dwyer, T. C. Hamilton, F. P. LaCreta, et al., "Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer, " Journal of Clinical Oncology, vol. 14, no. 1, pp. 249-256, 1996.
74. N. Sata, H. Stumpe-Klonowski, B. Han, D. Haussinger, and C. Niederau, "Menadione induces both necrosis and apoptosis in rat pancreatic acinar AR4-2J cells, " Free Radical Biology and Medicine, vol. 23, no. 6, pp. 844-850, 1997.
75. M. Hallak, T. Win, O. Shpilberg, et al., "Theanti-leukaemic activity of novel synthetic naphthoquinones against acute myeloid leukaemia: induction of cell death via the triggering of multiple signalling pathways, " British Journal of Haematology, vol. 147, no. 4, pp. 459-470, 2009.
76. K. A. Margolin, S. A. Akman, L. A. Leong, et al., "Phase I study of mitomycin C andmenadione in advanced solid tumors, " Cancer Chemotherapy and Pharmacology, vol. 36, no. 4, pp. 293-298, 1995.
77. M. Tetef, K. Margolin, C. Ahn, et al., "Mitomycin C and menadione for the treatment of lung cancer: a phase II trial, " Investigational New Drugs, vol. 13, no. 2, pp. 157-162, 1995.
78. K. Dvorakova, C. M. Payne, M. E. Tome, M. M. Briehl, T. McClure, and R. T. Dorr, "Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon, " Biochemical Pharmacology, vol. 60, no. 6, pp. 749-758, 2000.
79. A. F. Baker, T. Landowski, R. Dorr, et al., "The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response, " Clinical Cancer Research, vol. 13, no. 11, pp. 3388-3394, 2007.
80. S. Moulder, N. Dhillon, C. Ng, et al., "Aphase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer, " Investigational New Drugs, vol. 28, no. 5, pp. 634-640, 2010.
81. S. J. Cohen, M. M. Zalupski, M. R. Modiano, et al., "A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer, " Cancer Chemotherapy and Pharmacology, vol. 66, no. 2, pp. 287-294, 2010.
82. P. M. Barr, T. P. Miller, J. W. Friedberg, et al., "Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory Bcell non-Hodgkin lymphoma, " Blood, vol. 124, no. 8, pp. 1259-1265, 2014.
83. F. R. Kona, D. Buac, and A. M. Burger, "Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasomesystemin both preclinical and clinical studies, " Current CancerDrug Targets, vol. 11, no. 3, pp. 338-346, 2011.
84. J. Zha, F. Chen, H. Dong, et al., "Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition, " Journal of Translational Medicine, vol. 12, no. 1, article 163, 2014.
85. A. L. Furfaro, S. Piras, M. Passalacqua, et al., "HO-1 upregulation: a key point in high-risk neuroblastoma resistance to bortezomib, " Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1842, no. 4, pp. 613-622, 2014.
86. T. Hideshima, P. Richardson, D. Chauhan, et al., "The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells, " Cancer Research, vol. 61, no. 7, pp. 3071-3076, 2001.
87. M. H. Ma, H. H. Yang, K. Parker, et al., "The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents, " Clinical Cancer Research, vol. 9, no. 3, pp. 1136-1144, 2003.
88. S. Faderl, K. Rai, J. Gribben, et al., "Phase II study of singleagent bortezomib for the treatment of patientswith fludarabinerefractory B-cell chronic lymphocytic leukemia, " Cancer, vol. 107, no. 5, pp. 916-924, 2006.
89. L. M. Staudt, "Gene expression profiling of lymphoidmalignancies, " Annual Review of Medicine, vol. 53, pp. 303-318, 2002.
90. P. G. Richardson, B. Barlogie, J. Berenson, et al., "A phase 2 study of Bortezomib in relapsed, refractory myeloma, " The New England Journal of Medicine, vol. 348, no. 26, pp. 2609-2617, 2003.
91. D. M. Townsend, C. J. Pazoles, and K. D. Tew, "NOV-002, a mimetic of glutathione disulfide, " Expert Opinion on Investigational Drugs, vol. 17, no. 7, pp. 1075-1083, 2008.
92. P. Fidias and S. Novello, "Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer, " Journal of Clinical Oncology, vol. 28, no. 34, pp. 5116-5123, 2010.
93. A. J. Montero, C. M. Diaz-Montero, Y. E. Deutsch, et al., "Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer, " Breast Cancer Research and Treatment, vol. 132, no. 1, pp. 215-223, 2012.
94. A. Raza, N. Galili, S. Smith, et al., "Phase 1 multicenter doseescalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome, " Blood, vol. 113, no. 26, pp. 6533-6540, 2009.
95. A. F. Baker, T. Dragovich, W. R. Tate, et al., "The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma, " Journal of Laboratory and Clinical Medicine, vol. 147, no. 2, pp. 83-90, 2006.
96. G.-Z. Li, H.-F. Liang, B. Liao, et al., "Px-12 inhibits the growth of hepatocelluar carcinoma by inducing S-phase arrest, ROSdependent apoptosis and enhances 5-FU cytotoxicity, " American Journal of Translational Research, vol. 7, no. 9, pp. 1528-1540, 2015.
97. R. K. Ramanathan, M. Fakih, S. Mani, et al., "Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers, " Cancer Chemotherapy and Pharmacology, vol. 57, no. 4, pp. 465-474, 2006.
98. E. Boven, M. Verschraagen, T. M. Hulscher, et al., "BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts, " European Journal of Cancer, vol. 38, no. 8, pp. 1148-1156, 2002.
99. F. H. Hausheer, D. Shanmugarajah, B. D. Leverett, et al., "Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase, " Cancer Chemotherapy and Pharmacology, vol. 65, no. 5, pp. 941-951, 2010.
100. R. J. Amato, J. Jac, and J. Hernandez-Mcclain, "Motexafin gadolinium for the treatment ofmetastatic renal cell carcinoma: phase II study results, " Clinical Genitourinary Cancer, vol. 6, no. 2, pp. 73-78, 2008.
101. T. S. Lin, L. Naumovski, P. S. Lecane, et al., "Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia, " Leukemia and Lymphoma, vol. 50, no. 12, pp. 1977-1982, 2009.
102. M. P. Mehta, P. Rodrigus, C. H. J. Terhaard, et al., "Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases, " Journal of ClinicalOncology, vol. 21, no. 13, pp. 2529-2536, 2003.
103. C. Robert, B. Karaszewska, J. Schachter, et al., "Improved overall survival in melanoma with combined dabrafenib and trametinib, "The New England Journal of Medicine, vol. 372, no. 1, pp. 30-39, 2015.
104. T. Troiani, L. Vecchione, E. Martinelli, et al., "Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMPdependent protein kinase A activation in human lung and colorectal cancer cells, " British Journal of Cancer, vol. 106, no. 10, pp. 1648-1659, 2012.
105. J. Farley, W. E. Brady, V. Vathipadiekal, et al., "Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study, " The Lancet Oncology, vol. 14, no. 2, pp. 134-140, 2013.
106. A. L. Ho, R. K. Grewal, R. Leboeuf, et al., "Selumetinibenhanced radioiodine uptake in advanced thyroid cancer, " The New England Journal of Medicine, vol. 368, no. 7, pp. 623-632, 2013.
107. K. Horgan, E. Cooke, M. B. Hallett, and R. E. Mansel, "Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity, " Biochemical Pharmacology, vol. 35, no. 24, pp. 4463-4465, 1986.
108. W. T. Couldwell, M. H. Weiss, C. M. DeGiorgio, et al., "Clinical and radiographic response in a minority of patients with recurrentmalignant gliomas treated with high-dose tamoxifen, " Neurosurgery, vol. 32, no. 3, pp. 485-490, 1993.
109. P. A. Tang, G. Roldan, P. M. A. Brasher, et al., "A phase II study of carboplatin and chronic high-dose tamoxifen in patientswith recurrentmalignant glioma, " Journal ofNeuro-Oncology, vol. 78, no. 3, pp. 311-316, 2006.
110. V. C. Jordan, "Molecular mechanisms of antiestrogen action in breast cancer, " Breast Cancer Research and Treatment, vol. 31, no. 1, pp. 4152, 1994.
111. S. A. Nazarali and S. A. Narod, "Tamoxifen for women at high risk of breast cancer, " Breast Cancer: Targets andTherapy, vol. 6, pp. 29-36, 2014.
112. J. J. Gills and P. A. Dennis, "Perifosine: update on a novel Akt inhibitor, " Current Oncology Reports, vol. 11, no. 2, pp. 102-110, 2009.
113. L. Van Ummersen, K. Binger, J. Volkman, et al., "A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer, " Clinical Cancer Research, vol. 10, no. 22, pp. 7450-7456, 2004.
114. S. R. Vink, J. H. M. Schellens, J. H. Beijnen, et al., "Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours, " Radiotherapy and Oncology, vol. 80, no. 2, pp. 207-213, 2006.
115. I. M. Ghobrial, A. Roccaro, F. Hong, et al., "Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstroms macroglobulinemia, " Clinical Cancer Research, vol. 16, no. 3, pp. 1033-1041, 2010.
116. P. G. Richardson, J. Wolf, A. Jakubowiak, et al., "Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial, " Journal of Clinical Oncology, vol. 29, no. 32, pp. 4243-4249, 2011.
117. C. K. Weber, S. Liptay, T. Wirth, G. Adler, and R. M. Schmid, "Suppression of NF-κB activity by sulfasalazine ismediated by direct inhibition of IκB kinases α and β, " Gastroenterology, vol. 119, no. 5, pp. 1209-1218, 2000.
118. M.-Z. Ma, G. Chen, P. Wang, et al., "Xc-inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism, " Cancer Letters, vol. 368, no. 1, pp. 88-96, 2015.
119. W. A. Chow, C. Jiang, and M. Guan, "Anti-HIV drugs for cancer therapeutics: back to the future?" The Lancet Oncology, vol. 10, no. 1, pp. 61-71, 2009.
120. A. C. Hoover, M. M. Milhem, C. M. Anderson, et al., "Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: results of a phase II clinical trial, " Head and Neck, vol. 37, no. 5, pp. 722-726, 2015.
121. T. B. Brunner, M. Geiger, G. G. Grabenbauer, et al., "Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer, " Journal of Clinical Oncology, vol. 26, no. 16, pp. 2699-2706, 2008.
122. R. Rengan, R. Mick, D. Pryma, et al., "Aphase I trial of theHIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response, " Journal of Thoracic Oncology, vol. 7, no. 4, pp. 709-715, 2012.
123. S. Ackermann, M. W. Beckmann, F. Thiel, and T. Bogenrieder, "Topotecan in cervical cancer, " International Journal of Gynecological Cancer, vol. 17, no. 6, pp. 1215-1223, 2007.
124. D. K. Armstrong, M. A. Bookman, W. McGuire, R. E. Bristow, and J. M. Schilder, "A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study, " Gynecologic Oncology, vol. 105, no. 3, pp. 667-671, 2007.
125. J. L. Marshall, S. G. Eisenberg, M. D. Johnson, et al., "A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer, " Clinical Colorectal Cancer, vol. 4, no. 4, pp. 268-274, 2004.
126. A. W. Tolcher, L. Reyno, P. M. Venner, et al., "A randomized Phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormonerefractory prostate cancer, " Clinical Cancer Research, vol. 8, no. 8, pp. 2530-2535, 2002.
127. S. Rao, D. Watkins, D. Cunningham, et al., "Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkins lymphoma, " Annals of Oncology, vol. 15, no. 9, pp. 1413-1418, 2004.
128. D. Fabbro, S. Ruetz, S. Bodis, et al., "PKC412-a protein kinase inhibitor with a broad therapeutic potential, " Anti-Cancer Drug Design, vol. 15, no. 1, pp. 17-28, 2000.
129. M. J. Millward, C. House, D. Bowtell, et al., "The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study, " British Journal of Cancer, vol. 95, no. 7, pp. 829-834, 2006.
130. T. A. Yap, L. Yan, A. Patnaik, et al., "First-in-man clinical trial of the oral pan-AKT inhibitor MK-206 in patients with advanced solid tumors, " Journal of Clinical Oncology, vol. 29, no. 35, pp. 4688-4695, 2011.
131. M. A. Smith, R. Gorlick, E. A. Kolb, et al., "Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program, " Pediatric Blood and Cancer, vol. 59, no. 2, pp. 329-332, 2012.
132. K. K. Hoe, C. S. Verma, and D. P. Lane, "Drugging the p53 pathway: understanding the route to clinical efficacy, " Nature Reviews Drug Discovery, vol. 13, no. 3, pp. 217-236, 2014.
133. J. M. R. Lambert, P. Gorzov, D. B. Veprintsev, et al., "PRIMA-1 reactivatesmutant p53 by covalent binding to the core domain, " Cancer Cell, vol. 15, no. 5, pp. 376-388, 2009.
134. Y. Rew and D. Sun, "Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer, " Journal of Medicinal Chemistry, vol. 57, no. 15, pp. 6332-6341, 2014.
135. L. Zhang, K. Wang, Y. Lei, Q. Li, E. C. Nice, and C. Huang, "Redox signaling: potential arbitrator of autophagy and apoptosis in therapeutic response, " Free Radical Biology and Medicine, vol. 89, pp. 452-465, 2015.
136. G. E. N. Kass, S. K. Duddy, and S. Orrenius, "Activation of hepatocyte protein kinase C by redox-cycling quinones, " Biochemical Journal, vol. 260, no. 2, pp. 499-507, 1989.
137. X. Sun, F. Wu, R. Datta, S. Kharbanda, and D. Kufe, "Interaction between protein kinase Cδ and the c-Abl tyrosine kinase in the cellular response to oxidative stress, " The Journal of Biological Chemistry, vol. 275, no. 11, pp. 7470-7473, 2000.
138. R. Gopalakrishna and W. B. Anderson, "Ca2+-and phospholipid-independent activation of protein kinase C by selective oxidativemodification of the regulatory domain, " Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 17, pp. 6758-6762, 1989.
139. M. A. Pronzato, D. Cottalasso, C. Domenicotti, et al., "Effects of CC14 poisoning on metabolism of dolichol in RAT liver microsomes and golgi apparatus, " Free Radical Research, vol. 11, no. 4-5, pp. 267-277, 1990.
140. M. A. Pronzato, C. Domenicotti, F. Biasi, et al., "Inactivation of hepatocyte protein kinase C by carbon tetrachloride: involvement of drugs metabolic activation and prooxidant effect, " Biochemical and Biophysical Research Communications, vol. 171, no. 3, pp. 1353-1360, 1990.
141. C. Domenicotti, D. Paola, A. Vitali, et al., "Mechanisms of inactivation of hepatocyte protein kinase C isoforms following acute ethanol treatment, "FreeRadical BiologyandMedicine, vol. 25, no. 4-5, pp. 529-535, 1998.
142. C. Domenicotti, D. Paola, A. Vitali, et al., "Ethanol-induced effects on expression level, activity, and distribution of protein kinase C isoforms in rat liver Golgi apparatus, " Chemico-Biological Interactions, vol. 114, no. 1-2, pp. 33-43, 1998.
143. C. E. Antal, A. M. Hudson, E. Kang, et al., "Cancer-associated protein kinase C mutations reveal kinases role as tumor suppressor, " Cell, vol. 160, no. 3, pp. 489-502, 2015.
144. L. Langzam, R. Koren, R. Gal, et al., "Patterns of protein kinase C isoenzyme expression in transitional cell carcinoma of bladder relation to degree of malignancy, " American Journal of Clinical Pathology, vol. 116, no. 3, pp. 377-385, 2001.
145. G. W. Neill, L. R. Ghali, J. L. Green, M. S. Ikram, M. P. Philpott, and A. G. Quinn, "Loss of protein kinase Cδ expression may enhance the tumorigenic potential of Gli1 in basal cell carcinoma, " Cancer Research, vol. 63, no. 15, pp. 4692-4697, 2003.
146. H. Oster and M. Leitges, "Protein kinase Cδ but not PKCζ suppresses intestinal tumor formation in ApcMin/+ mice, " Cancer Research, vol. 66, no. 14, pp. 6955-6963, 2006.
147. Y. Gokmen-Polar, N. R. Murray, M. A. Velasco, Z. Gatalica, and A. P. Fields, "Elevated protein kinase CβII is an early promotive event in colon carcinogenesis, " Cancer Research, vol. 61, no. 4, pp. 1375-1381, 2001.
148. W. Yu, N. R. Murray, C. Weems, et al., "Role of cyclooxygenase 2 in protein kinase CβII-mediated colon carcinogenesis, " Journal of Biological Chemistry, vol. 278, no. 13, pp. 11167-11174, 2003.
149. E. Migliaccio, M. Giogio, S. Mele, et al., "The p66shc adaptor protein controls oxidative stress response and life span in mammals, " Nature, vol. 402, no. 6759, pp. 309-313, 1999.
150. J. Wang, M. Shao, M. Liu, et al., "PKCα promotes generation of reactive oxygen species via DUOX2 in hepatocellular carcinoma, " Biochemical and Biophysical Research Communications, vol. 463, no. 4, pp. 839-845, 2015.
151. M. Nitti, A. L. Furfaro, C. Cevasco, et al., "PKC delta and NADPH oxidase in retinoic acid-induced neuroblastoma cell differentiation, " Cellular Signalling, vol. 22, no. 5, pp. 828-835, 2010.
152. D. N. Jackson and D. A. Foster, "The enigmatic protein kinase Cδ: complex roles in cell proliferation and survival, " The FASEB Journal, vol. 18, no. 6, pp. 627-636, 2004.
153. N. A. Riobo, G. M. Haines, and C. P. Emerson Jr., "Protein kinase C-δ and mitogen-activated protein/extracellular signalregulated kinase-1 control GLI activation in hedgehog signaling, " Cancer Research, vol. 66, no. 2, pp. 839-845, 2006.
154. E. M. Griner and M. G. Kazanietz, "Protein kinase C and other diacylglycerol effectors in cancer, " Nature Reviews Cancer, vol. 7, no. 4, pp. 281-294, 2007.
155. S. M. Nabha, S. Glaros, M. Hong, et al., "Upregulation of PKC-δ contributes to antiestrogen resistance inmammary tumor cells, " Oncogene, vol. 24, no. 19, pp. 3166-3176, 2005.
156. B. Marengo, C. de Ciucis, R. Ricciarelli, et al., "PKCδ sensitizes neuroblastoma cells to L-buthionine-sulfoximine and etoposide inducing reactive oxygen species overproduction and DNA damage, " PLoS ONE, vol. 6, no. 2, article e14661, 2011.
157. A. R. M. Ruhul Amin, T. Senga, M. L. Oo, A. A. Thant, and M. Hamaguchi, "Secretion ofmatrixmetalloproteinase-9 by the proinflammatory cytokine, IL-1β: a role for the dual signalling pathways, Akt and Erk, " Genes to Cells, vol. 8, no. 6, pp. 515-523, 2003.
158. L. Chang, P. H. Graham, J. Hao, et al., "Acquisition of epithelialmesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance, " Cell Death and Disease, vol. 4, no. 10, article e875, 2013.
159. S. S. Kang, T. Kwon, D. Y. Kwon, and S. I. Do, "Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit, " Journal of Biological Chemistry, vol. 274, no. 19, pp. 13085-13090, 1999.
160. G. Leonarduzzi, B. Sottero, G. Testa, F. Biasi, and G. Poli, "New insights into redox-modulated cell signaling, " Current Pharmaceutical Design, vol. 17, no. 36, pp. 3994-4006, 2011.
161. M. Los, S. Maddika, B. Erb, and K. Schulze-Osthoff, "Switching Akt: fromsurvival signaling to deadly response, " BioEssays, vol. 31, no. 5, pp. 492-495, 2009.
162. J. Xu, W. Tian, X. Ma, et al., "The molecular mechanism underlying morphine-induced akt activation: roles of protein phosphatases and reactive oxygen species, " Cell Biochemistry and Biophysics, vol. 61, no. 2, pp. 303-311, 2011.
163. N. R. Leslie, "The redox regulation of PI 3-kinase-dependent signaling, " Antioxidants and Redox Signaling, vol. 8, no. 9-10, pp. 1765-1774, 2006.
164. H. Ichijo, E. Nishida, K. Irie, et al., "Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways, " Science, vol. 275, no. 5296, pp. 90-94, 1997.
165. E. H. Goldman, L. Chen, and H. Fu, "Activation of apoptosis signal-regulating kinase 1 by reactive oxygen species through dephosphorylation at serine 967 and 14-3-3 dissociation, " Journal of Biological Chemistry, vol. 279, no. 11, pp. 10442-10449, 2004.
166. M. Saitoh, H. Nishitoh, M. Fujii, et al., "Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1, " The EMBO Journal, vol. 17, no. 9, pp. 2596-2606, 1998.
167. T. M. Thornton and M. Rincon, "Non-classical p38 map kinase functions: cell cycle checkpoints and survival, " International Journal of Biological Sciences, vol. 5, no. 1, pp. 44-52, 2009.
168. L. Hui, L. Bakiri, A. Mairhorfer, et al., "p38α suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway, " Nature Genetics, vol. 39, no. 6, pp. 741-749, 2007.
169. J. J. Ventura, S. Tenbaum, E. Perdigueroet al., "p38α MAPkinase is essential in lung stem and progenitor cell proliferation and differentiation, " Nature Genetics, vol. 39, no. 6, pp. 750-758, 2007.
170. M.-S. Kim, E.-J. Lee, H.-R. C. Kim, and A. Moon, "p38 kinase is a key signaling molecule for H-ras-induced cell motility and invasive phenotype in human breast epithelial cells, " Cancer Research, vol. 63, no. 17, pp. 5454-5461, 2003.
171. L. C. Platanias, "Map kinase signaling pathways and hematologic malignancies, " Blood, vol. 101, no. 12, pp. 4667-4679, 2003.
172. D. Halawani, R. Mondeh, L.-A. Stanton, and F. Beier, "p38 MAP kinase signaling is necessary for rat chondrosarcoma cell proliferation, " Oncogene, vol. 23, no. 20, pp. 3726-3731, 2004.
173. B. Marengo, C. G. De Ciucis, R. Ricciarelli, et al., "P38MAPK inhibition: a new combined approach to reduce neuroblastoma resistance under etoposide treatment, " Cell Death and Disease, vol. 4, article e589, 2013.
174. X. Shi, Y. Zhang, J. Zheng, and J. Pan, "Reactive oxygen species in cancer stem cells, " Antioxidants and Redox Signaling, vol. 16, no. 11, pp. 1215-1228, 2012.
175. C. Cosentino, D. Grieco, and V. Costanzo, "ATMactivates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair, " EMBO Journal, vol. 30, no. 3, pp. 546-555, 2011.
176. H. Yin and J. Glass, "The phenotypic radiation resistance of CD44+/CD24(-or low) breast cancer cells is mediated through the enhanced activation of ATM signaling, " PLoS ONE, vol. 6, no. 9, Article IDe24080, 2011.
177. A. Molchadsky, N. Rivlin, R. Brosh, V. Rotter, and R. Sarig, "P53 is balancing development, differentiation and de-differentiation to assure cancer prevention, " Carcinogenesis, vol. 31, no. 9, pp. 1501-1508, 2010.
178. Y. Haupt, R. Maya, A. Kazaz, and M. Oren, "Mdm2 promotes the rapid degradation of p53, " Nature, vol. 387, no. 6630, pp. 296-299, 1997.
179. A. M. Bode and Z. Dong, "Post-translational modification of p53 in tumorigenesis, " Nature Reviews Cancer, vol. 4, no. 10, pp. 793-805, 2004.
180. J.-P. Kruse and W. Gu, "Modes of p53 regulation, " Cell, vol. 137, no. 4, pp. 609-622, 2009.
181. K. Polyak, Y. Xia, J. L. Zweier, K. W. Kinzler, and B. Vogelstein, "A model for p53-induced apoptosis, " Nature, vol. 389, no. 6648, pp. 300-305, 1997.
182. A. Rivera and S. A. Maxwell, "The p53-induced gene-6 (proline oxidase) mediates apoptosis through a calcineurin-dependent pathway, " Journal of Biological Chemistry, vol. 280, no. 32, pp. 29346-29354, 2005.
183. A. A. Sablina, A. V. Budanov, G. V. Ilyinskaya, L. S. Agapova, J. E. Kravchenko, and P. M. Chumakov, "Theantioxidant function of the p53 tumor suppressor, " Nature Medicine, vol. 11, no. 12, pp. 1306-1313, 2005.
184. D. Italiano, A. M. Lena, G. Melino, and E. Candi, "Identification of NCF2/p67phox as a novel p53 target gene, " Cell Cycle, vol. 11, no. 24, pp. 4589-4596, 2012.
185. K. H. Vousden and K. M. Ryan, "P53 and metabolism, " Nature Reviews Cancer, vol. 9, no. 10, pp. 691-700, 2009.
186. S. P. Hussain, P. Amstad, P. He, et al., "p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis, " Cancer Research, vol. 64, no. 7, pp. 2350-2356, 2004.
187. S. Y. Nam and K. Sabapathy, "P53 promotes cellular survival in a context-dependent manner by directly inducing the expression of haeme-oxygenase-1, " Oncogene, vol. 30, no. 44, pp. 4476-4486, 2011.
188. K. Bensaad, A. Tsuruta, M. A. Selak, et al., "TIGAR, a p53-inducible regulator of glycolysis and apoptosis, " Cell, vol. 126, no. 1, pp. 107-120, 2006.
189. C. Gorrini, I. S. Harris, and T. W. Mak, "Modulationof oxidative stress as an anticancer strategy, " Nature Reviews Drug Discovery, vol. 12, no. 12, pp. 931-947, 2013.
190. W. Hu, C. Zhang, R. Wu, Y. Sun, A. Levine, and Z. Feng, "Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 16, pp. 7455-7460, 2010.
191. R. Hu, C. L. Saw, R. Yu, and A.-N. Kong, "Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory, " Antioxidants and Redox Signaling, vol. 13, no. 11, pp. 1679-1698, 2010.
192. N. Wakabayashi, S. L. Slocum, J. J. Skoko, S. Shin, and T. W. Kensler, "When NRF2 talks, whos listening?" Antioxidants and Redox Signaling, vol. 13, no. 11, pp. 1649-1663, 2010.
193. C. J. Harvey, R. K. Thimmulappa, A. Singh, et al., "Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress, " Free Radical Biology and Medicine, vol. 46, no. 4, pp. 443-453, 2009.
194. J. Nordberg and E. S. J. Arner, "Reactive oxygen species, antioxidants, and the mammalian thioredoxin system, " Free Radical Biology andMedicine, vol. 31, no. 11, pp. 1287-1312, 2001.
195. B. Padmanabhan, K. I. Tong, T. Ohta, et al., "Structural basis for defects of Keap1 activity provoked by its pointmutations in lung cancer, " Molecular Cell, vol. 21, no. 5, pp. 689-700, 2006.
196. A. Singh, V. Misra, R. K. Thimmulappa, et al., "Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer, " PLoS Medicine, vol. 3, no. 10, article e420, 2006.
197. T. Ohta, K. Iijima, M. Miyamoto, et al., "Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth, " Cancer Research, vol. 68, no. 5, pp. 1303-1309, 2008.
198. P. Nioi and T. Nguyen, "A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity, " Biochemical and Biophysical Research Communications, vol. 362, no. 4, pp. 816-821, 2007.
199. T. Shibata, T. Ohta, K. I. Tong, et al., "Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 36, pp. 13568-13573, 2008.
200. S. Devarakonda, D. Morgensztern, and R. Govindan, "Genomic alterations in lung adenocarcinoma, " The Lancet Oncology, vol. 16, no. 7, pp. e342-e351, 2015.
201. E. S. J. Arner and A. Holmgren, "Physiological functions of thioredoxin and thioredoxin reductase, " European Journal of Biochemistry, vol. 267, no. 20, pp. 6102-6109, 2000.
202. A. You, C.-W. Nam, N. Wakabayashi, M. Yamamoto, T. W. Kensler, and M.-K. Kwak, "Transcription factor Nrf2 maintains the basal expression of Mdm2: an implication of the regulation of p53 signaling by Nrf2, " Archives of Biochemistry and Biophysics, vol. 507, no. 2, pp. 356-364, 2011.
203. M. C. Jaramillo and D. D. Zhang, "The emerging role of the Nrf2-Keap1 signaling pathway in cancer, " Genes and Development, vol. 27, no. 20, pp. 2179-2191, 2013.
204. A. L. Furfaro, J. R. Z. MacAy, B. Marengo, et al., "Resistance of neuroblastoma GI-ME-N cell line to glutathione depletion involves Nrf2 and heme oxygenase-1, " Free Radical Biology and Medicine, vol. 52, no. 2, pp. 488-496, 2012.
205. Z. J. Chen, "Ubiquitin signalling in the NF-κB pathway, " Nature Cell Biology, vol. 7, no. 8, pp. 758-765, 2005.
206. S. Miyamoto, "Nuclear initiated NF-κB signaling: NEMO and ATMtake center stage, " Cell Research, vol. 21, no. 1, pp. 116-130, 2011.
207. M. J. Morgan and Z.-G. Liu, "Crosstalk of reactive oxygen species and NF-κB signaling, " Cell Research, vol. 21, no. 1, pp. 103-115, 2011.
208. L. Flohe, S. Toppo, G. Cozza, and F. Ursini, "A comparison of thiol peroxidase mechanisms, " Antioxidants and Redox Signaling, vol. 15, no. 3, pp. 763-780, 2011.
209. F. Antunes and D. Han, "Redox regulation of NF-κB: frombasic to clinical research, " Antioxidants and Redox Signaling, vol. 11, no. 9, pp. 2055-2056, 2009.
210. F. Wang, J. L. Yang, K. K. Yu, et al., "Activation of theNF-kappaB pathway as a mechanism of alcohol enhanced progression and metastasis of human hepatocellular carcinoma, " Molecular Cancer, vol. 14, no. 1, article 10, 2015.
211. K. B. Myant, P. Cammareri, E. J. McGhee, et al., "ROS production and NF-κB activation triggered by RAC1 facilitate WNTdriven intestinal stem cell proliferation and colorectal cancer initiation, " Cell Stem Cell, vol. 12, no. 6, pp. 761-773, 2013.
212. J. Grosjean-Raillard, M. Tailler, L. Ades, et al., "ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia, " Oncogene, vol. 28, no. 8, pp. 1099-1109, 2009.
213. R. R. Rosato, S. S. Kolla, S. K. Hock, et al., "Histone deacetylase inhibitors activate NF-κB in human leukemia cells through an ATM/NEMO-related pathway, " The Journal of Biological Chemistry, vol. 285, no. 13, pp. 10064-10077, 2010.
214. G. L. Wang, B.-H. Jiang, E. A. Rue, and G. L. Semenza, "Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellularO2 tension, " Proceedings of the NationalAcademy of Sciences of theUnited States ofAmerica, vol. 92, no. 12, pp. 5510-5514, 1995.
215. P. J. Kallio, I. Pongratz, K. Gradin, J. McGuire, and L. Poellinger, "Activation of hypoxia-inducible factor 1α: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor, " Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 11, pp. 5667-5672, 1997.
216. J.-W. Kim, P. Gao, Y.-C. Liu, G. L. Semenza, and C. V. Dang, "Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1, " Molecular and Cellular Biology, vol. 27, no. 21, pp. 7381-7393, 2007.
217. G. L. Semenza, "Targeting HIF-1 for cancer therapy, " Nature Reviews Cancer, vol. 3, no. 10, pp. 721-732, 2003.
218. G. L. Semenza, "Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics, " Oncogene, vol. 29, no. 5, pp. 625-634, 2010.
219. G. L. Semenza, "Regulation of cancer cell metabolism by hypoxia-inducible factor 1, " Seminars in Cancer Biology, vol. 19, no. 1, pp. 12-16, 2009.
220. S. Movafagh, S. Crook, and K. Vo, "Regulation of hypoxiainducible factor-1a by reactive oxygen species: new developments in an old debate, " Journal of Cellular Biochemistry, vol. 116, no. 5, pp. 696-703, 2015.
221. W. R. Wilson and M. P. Hay, "Targeting hypoxia in cancer therapy, " Nature Reviews Cancer, vol. 11, no. 6, pp. 393-410, 2011.
222. T. Ozben, "Oxidative stress and apoptosis: impact on cancer therapy, " Journal of Pharmaceutical Sciences, vol. 96, no. 9, pp. 2181-2196, 2007.
223. M. F. Renschler, "The emerging role of reactive oxygen species in cancer therapy, " European Journal of Cancer, vol. 40, no. 13, pp. 1934-1940, 2004.
224. B. K. Samulitis, T. H. Landowski, and R. T. Dorr, "Correlates of imexon sensitivity in human multiple myeloma cell lines, " Leukemia and Lymphoma, vol. 47, no. 1, pp. 97-109, 2006.
225. K. Dvorakova, C. M. Payne, M. E. Tome, et al., "Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells, " Molecular CancerTherapeutics, vol. 1, no. 3, pp. 185-195, 2002.
226. D. Cen, D. Brayton, B. Shahandeh, F. L. Meyskens Jr., and P. J. Farmer, "Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells, " Journal of Medicinal Chemistry, vol. 47, no. 27, pp. 6914-6920, 2004.
227. F.-T. Liu, S. G. Agrawal, J. G. Gribben, et al., "Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL, " Blood, vol. 111, no. 5, pp. 2797-2805, 2008.
228. J. Hou, A. Cui, P. Song, H. Hua, T. Luo, and Y. Jiang, "Reactive oxygen species-mediated activation of the Srcepidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells, " Molecular Medicine Reports, vol. 11, no. 1, pp. 712-718, 2015.
229. A. J. Montero and J. Jassem, "Cellular redox pathways as a therapeutic target in the treatment of cancer, " Drugs, vol. 71, no. 11, pp. 1385-1396, 2011.
230. U. A. Matulonis, N. S. Horowitz, S. M. Campos, et al., "Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer, " Journal of Clinical Oncology, vol. 26, no. 35, pp. 5761-5766, 2008.
231. D. M. Townsend and K. D. Tew, "Pharmacology of a mimetic of glutathione disulfide, NOV-002, " Biomedicine and Pharmacotherapy, vol. 63, no. 2, pp. 75-78, 2009.
232. D. Magda, P. Lecane, R. A. Miller, et al., "Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines, " Cancer Research, vol. 65, no. 9, pp. 3837-3845, 2005.
233. D. Magda and R. A. Miller, "Motexafin gadolinium: a novel redox active drug for cancer therapy, " Seminars in Cancer Biology, vol. 16, no. 6, pp. 466-476, 2006.